{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:11:55Z","timestamp":1793293915479,"version":"4.5.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.annonc.2020.11.005","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T04:22:17Z","timestamp":1606278137000},"page":"157-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":182,"title":["Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines\u2606"],"prefix":"10.1016","volume":"32","author":[{"given":"M.E.","family":"Lacouture","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Sibaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"van den Hurk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Fern\u00e1ndez-Pe\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Jahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2020.11.005_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/annonc\/mdx757","article-title":"European Society for Medical Oncology (ESMO) position paper on supportive and palliative care","volume":"29","author":"Jordan","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.11.005_bib2","first-page":"1462","article-title":"Dermatologic challenges in cancer patients and survivors","volume":"21","author":"Agha","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.annonc.2020.11.005_bib3","first-page":"267","article-title":"Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study","volume":"16","author":"Hackbarth","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.annonc.2020.11.005_bib4","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40257-013-0021-0","article-title":"Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic","volume":"14","author":"Rosen","year":"2013","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.annonc.2020.11.005_bib5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2020.11.005_bib6","doi-asserted-by":"crossref","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.11.005_bib7","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000112795","article-title":"Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results","volume":"72","author":"Boone","year":"2007","journal-title":"Oncology"},{"key":"10.1016\/j.annonc.2020.11.005_bib8","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/cncr.29918","article-title":"Beyond the dose-limiting toxicity period: dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program","volume":"122","author":"Drilon","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2020.11.005_bib9","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.annonc.2020.11.005_bib10","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","article-title":"Cutaneous adverse effects with HER1\/EGFR-targeted agents: is there a silver lining?","volume":"23","author":"Perez-Soler","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.11.005_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jnci\/djp439","article-title":"Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy","volume":"102","author":"Eilers","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.annonc.2020.11.005_bib12","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.2217\/fon.15.265","article-title":"Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis","volume":"11","author":"Abdel-Rahman","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.annonc.2020.11.005_bib13","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.11.005_bib14","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/ajd.12124","article-title":"Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib","volume":"55","author":"Anforth","year":"2014","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.annonc.2020.11.005_bib15","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1158\/1078-0432.CCR-10-0421","article-title":"Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1\/2 inhibitors in cancer patients","volume":"16","author":"Nardone","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2020.11.005_bib16","doi-asserted-by":"crossref","first-page":"199ra111","DOI":"10.1126\/scitranslmed.3005886","article-title":"Epidermal EGFR controls cutaneous host defense and prevents inflammation","volume":"5","author":"Lichtenberger","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.annonc.2020.11.005_bib17","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","article-title":"Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption","volume":"25","author":"Scope","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.11.005_bib18","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/cncr.23621","article-title":"Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)","volume":"113","author":"Jatoi","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2020.11.005_bib19","first-page":"1601","article-title":"Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB)","volume":"19","author":"Jatoi","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.annonc.2020.11.005_bib20","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.11.005_bib21","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1200\/JCO.2015.62.3918","article-title":"Pan Canadian rash trial: a randomized phase III trial evaluating the impact of a prophylactic skin treatment regimen on epidermal growth factor receptor-tyrosine kinase inhibitor-induced skin toxicities in patients with metastatic lung cancer","volume":"34","author":"Melosky","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.11.005_bib22","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/annonc\/mdy015","article-title":"EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity","volume":"29","author":"Hofheinz","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.11.005_bib23","first-page":"1079","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.annonc.2020.11.005_bib24","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1111\/ajd.12728","article-title":"Epidermal growth factor receptor inhibitor-induced papulopustular eruption successfully treated with low-dose oral dapsone","volume":"59","author":"Zhao","year":"2018","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.annonc.2020.11.005_bib25","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jaad.2014.03.019","article-title":"Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management","volume":"71","author":"Miller","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.annonc.2020.11.005_bib26","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.11.005_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1470-2045(12)70413-8","article-title":"Cutaneous toxicities of RAF inhibitors","volume":"14","author":"Anforth","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.11.005_bib28","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1007\/s10637-013-9977-0","article-title":"Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis","volume":"31","author":"Belum","year":"2013","journal-title":"Invest New Drugs"},{"issue":"3","key":"10.1016\/j.annonc.2020.11.005_bib29","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jaad.2019.04.021","article-title":"Risk of hand-foot skin reaction associated with VEGFR-TKIs: a meta-analysis of 57 randomized controlled trials involving 24956 patients","volume":"83","author":"Ding","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.annonc.2020.11.005_bib30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/bjc.2015.419","article-title":"Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer","volume":"114","author":"Zielinski","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2020.11.005_bib31","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1093\/annonc\/mds145","article-title":"Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study","volume":"23","author":"Poprach","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.11.005_bib32","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/bjc.2011.227","article-title":"Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial","volume":"105","author":"Stintzing","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2020.11.005_bib33","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.11.005_bib34","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1634\/theoncologist.2008-0131","article-title":"Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"13","author":"Lacouture","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2020.11.005_bib35","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1200\/JCO.2013.52.9651","article-title":"Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma","volume":"33","author":"Ren","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.11.005_bib36","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2014.60.4587","article-title":"Mapisal versus urea cream as prophylaxis for capecitabine-associated hand-foot syndrome: a randomized phase III\u00a0trial of the AIO quality of life working group","volume":"33","author":"Hofheinz","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.11.005_bib37","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1200\/JCO.2005.15.651","article-title":"Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand","volume":"23","author":"Scotte","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.11.005_bib38","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/cncr.23333","article-title":"Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot","volume":"112","author":"Scotte","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2020.11.005_bib39","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/ced.12538","article-title":"Prophylactic and therapeutic efficacy of pyridoxine supplements in the management of hand-foot syndrome during chemotherapy: a meta-analysis","volume":"40","author":"Jo","year":"2015","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.annonc.2020.11.005_bib40","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/annonc\/mdr400","article-title":"Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial","volume":"23","author":"Zhang","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.11.005_bib41","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00432-010-0958-9","article-title":"The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II\/III colorectal cancer: a phase II randomized prospective study","volume":"137","author":"Zhang","year":"2011","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.annonc.2020.11.005_bib42","first-page":"481","article-title":"Supportive treatments for patients with cancer","volume":"114","author":"Jordan","year":"2017","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.annonc.2020.11.005_bib43","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2217\/mmt-2017-0015","article-title":"Management of the cutaneous adverse effects of antimelanoma therapy","volume":"4","author":"Liu","year":"2017","journal-title":"Melanoma Manag"},{"key":"10.1016\/j.annonc.2020.11.005_bib44","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.11.005_bib45","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S1470-2045(12)70553-3","article-title":"Pathobiology of chemotherapy-induced hair loss","volume":"14","author":"Paus","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.11.005_bib46","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1634\/theoncologist.2013-0193","article-title":"Alopecia with endocrine therapies in patients with cancer","volume":"18","author":"Saggar","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2020.11.005_bib47","first-page":"2697","article-title":"A\u00a0prospective study of aromatase inhibitor therapy initiation and self-reported side effects","volume":"25","author":"Gallicchio","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.annonc.2020.11.005_bib48","series-title":"The MASCC Textbook of Cancer Supportive Care and Survivorship","author":"Freites-Martinez","year":"2018"},{"key":"10.1016\/j.annonc.2020.11.005_bib49","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/jamadermatol.2018.0454","article-title":"Endocrine therapy-induced alopecia in patients with breast cancer","volume":"154","author":"Freites-Martinez","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annonc.2020.11.005_bib50","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jaad.2018.03.055","article-title":"Hair disorders in patients with cancer","volume":"80","author":"Freites-Martinez","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.annonc.2020.11.005_bib51","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jama.2016.20939","article-title":"Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial","volume":"317","author":"Nangia","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.annonc.2020.11.005_bib52","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.clbc.2017.07.012","article-title":"Scalp hypothermia for preventing alopecia during chemotherapy. A systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Rugo","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.annonc.2020.11.005_bib53","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/ijd.13261","article-title":"Hair \u201cregrowth\u201d during chemotherapy after scalp cooling technique","volume":"55","author":"Sahadevan","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.annonc.2020.11.005_bib54","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10549-017-4185-9","article-title":"Scalp cooling with adjuvant\/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis","volume":"163","author":"Rugo","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.annonc.2020.11.005_bib55","first-page":"507","article-title":"Misuse of scalp hypothermia","volume":"65","author":"Witman","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.annonc.2020.11.005_bib56","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10549-011-1453-y","article-title":"Breast cancer scalp metastasis as first metastatic site after scalp cooling: two cases of occurrence after 7- and 9-year follow-up","volume":"128","author":"Lemieux","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.annonc.2020.11.005_bib57","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2340\/00015555-0305","article-title":"Clinical classification of itch: a position paper of the International Forum for the Study of Itch","volume":"87","author":"Stander","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.annonc.2020.11.005_bib58","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jaad.2013.06.038","article-title":"Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis","volume":"69","author":"Ensslin","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.annonc.2020.11.005_bib59","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.critrevonc.2015.05.007","article-title":"Risk of pruritus in cancer patients treated with biological therapies: a systematic review and meta-analysis of clinical trials","volume":"96","author":"Santoni","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.annonc.2020.11.005_bib60","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2020.11.005_bib61","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaad.2006.04.062","article-title":"Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients","volume":"55","author":"Roe","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.annonc.2020.11.005_bib62","first-page":"17","article-title":"Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis","volume":"14","author":"Monroe","year":"1992","journal-title":"Clin Ther"},{"key":"10.1016\/j.annonc.2020.11.005_bib63","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1345\/aph.1G078","article-title":"Pregabalin: a new neuromodulator with\u00a0broad therapeutic indications","volume":"39","author":"Shneker","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.annonc.2020.11.005_bib64","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jpainsymman.2006.07.006","article-title":"Efficacy of pregabalin in the management of cetuximab-related itch","volume":"32","author":"Porzio","year":"2006","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.annonc.2020.11.005_bib65","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(12)70373-X","article-title":"Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study","volume":"13","author":"Santini","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.11.005_bib66","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.lungcan.2017.04.020","article-title":"Aprepitant for refractory nivolumab-induced pruritus","volume":"109","author":"Ito","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.annonc.2020.11.005_bib67","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(14)71133-7","article-title":"Nail toxicities induced by systemic anticancer treatments","volume":"16","author":"Robert","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.11.005_bib68","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jaad.2014.07.033","article-title":"Cutaneous adverse effects of targeted therapies: part II: inhibitors of intracellular molecular signaling pathways","volume":"72","author":"Macdonald","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.annonc.2020.11.005_bib69","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jaad.2013.02.025","article-title":"Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer","volume":"69","author":"Kiyohara","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.annonc.2020.11.005_bib70","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2011.10.009","article-title":"The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis","volume":"67","author":"Garden","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.annonc.2020.11.005_bib71","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1001\/jamadermatol.2015.4448","article-title":"Comparison of skin toxic effects associated with gefitinib, erlotinib, or afatinib treatment for non-small cell lung cancer","volume":"152","author":"Chen","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annonc.2020.11.005_bib72","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1684\/ejd.2016.2833","article-title":"Dermatological adverse events with taxane chemotherapy","volume":"26","author":"Sibaud","year":"2016","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.annonc.2020.11.005_bib73","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000490177","article-title":"Relationship between paronychia and drug concentrations of epidermal growth factor receptor tyrosine kinase inhibitors","volume":"95","author":"Masago","year":"2018","journal-title":"Oncology"},{"key":"10.1016\/j.annonc.2020.11.005_bib74","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1468-3083.2009.03516.x","article-title":"Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia","volume":"24","author":"Eames","year":"2010","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annonc.2020.11.005_bib75","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaad.2017.08.038","article-title":"The microbial flora of taxane therapy-associated nail disease in cancer patients","volume":"78","author":"Virgen","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.annonc.2020.11.005_bib76","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/jdv.15121","article-title":"Using a novel scoring system for paronychia related to oncologic treatments (SPOT) for assessing paronychia severity and its correlation with pain index and quality of life","volume":"33","author":"Ho","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annonc.2020.11.005_bib77","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1365-2133.2010.09906.x","article-title":"Periungual and subungual pyogenic granuloma","volume":"163","author":"Piraccini","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annonc.2020.11.005_bib78","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2147\/CCID.S90542","article-title":"Chemotherapy-associated paronychia treated with a dilute povidone-iodine\/dimethylsulfoxide preparation","volume":"8","author":"Capriotti","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.annonc.2020.11.005_bib79","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2147\/CMAR.S139301","article-title":"Chemotherapy-associated paronychia treated with 2% povidone-iodine: a series of cases","volume":"9","author":"Capriotti","year":"2017","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.annonc.2020.11.005_bib80","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1001\/jamadermatol.2017.4120","article-title":"Topical timolol for paronychia and pseudopyogenic granuloma in patients treated with epidermal growth factor receptor inhibitors and capecitabine","volume":"154","author":"Cubiro","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annonc.2020.11.005_bib81","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1468-3083.2006.01615.x","article-title":"Cryotherapy in the treatment of pyogenic granuloma","volume":"20","author":"Mirshams","year":"2006","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.annonc.2020.11.005_bib82","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/bjd.13743","article-title":"The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis","volume":"173","author":"Capriotti","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annonc.2020.11.005_bib83","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/annonc\/mdg050","article-title":"Taxane-induced nail changes: incidence, clinical presentation and outcome","volume":"14","author":"Minisini","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.11.005_bib84","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1078155208100450","article-title":"Nail toxicity induced by cancer chemotherapy","volume":"15","author":"Gilbar","year":"2009","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.annonc.2020.11.005_bib85","first-page":"1191","article-title":"Nail changes due to docetaxel\u2014a neglected side effect and nuisance for the patient","volume":"15","author":"Winther","year":"2007","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.annonc.2020.11.005_bib86","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.clindermatol.2013.06.013","article-title":"Drug-related nail disease","volume":"31","author":"Piraccini","year":"2013","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.annonc.2020.11.005_bib87","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/(SICI)1097-0142(20000515)88:10<2367::AID-CNCR22>3.0.CO;2-#","article-title":"Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature","volume":"88","author":"Hussain","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2020.11.005_bib88","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000486021","article-title":"Asymmetric acral spared phenomenon related to systemic anticancer therapies","volume":"4","author":"Baran","year":"2018","journal-title":"Skin Appendage Disord"},{"key":"10.1016\/j.annonc.2020.11.005_bib89","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1470-2045(15)00019-4","article-title":"Taxane-related nail toxicity","volume":"16","author":"Schepisi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.11.005_bib90","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10549-018-4788-9","article-title":"A\u00a0double-blind, randomised trial of a polyphenolic-rich nail bed balm for chemotherapy-induced onycholysis: the UK polybalm study","volume":"171","author":"Thomas","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.annonc.2020.11.005_bib91","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s10549-017-4268-7","article-title":"A\u00a0prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant\/adjuvant docetaxel chemotherapy","volume":"164","author":"Kim","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.annonc.2020.11.005_bib92","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jamadermatol.2018.3465","article-title":"Evaluation of prevention interventions for taxane-induced dermatologic adverse events: a systematic review","volume":"154","author":"Marks","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.annonc.2020.11.005_bib93","first-page":"2231","article-title":"A\u00a0systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies","volume":"23","author":"Chan","year":"2015","journal-title":"Support Care Cancer"},{"issue":"11","key":"10.1016\/j.annonc.2020.11.005_bib94","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/jnci\/djaa016","article-title":"Validity and reliability of the pediatric patient-reported outcomes \u2013 Common Terminology Criteria for Adverse Events","volume":"112","author":"Reeve","year":"2020","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.annonc.2020.11.005_bib95","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420431576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420431576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:01:19Z","timestamp":1760335279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753420431576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":95,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0923753420431576"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2020.11.005","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines\u2606","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2020.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}